Last reviewed 2026-04-23 · How we verify

Low phytic acid maize

NICHD Global Network for Women's and Children's Health · Phase 3 active Small molecule

Low phytic acid maize is a Small molecule drug developed by NICHD Global Network for Women's and Children's Health. It is currently in Phase 3 development for Micronutrient deficiency (iron and zinc) in populations with maize-dependent diets, Malnutrition in women and children in low-resource settings.

Low phytic acid maize reduces anti-nutritional phytic acid content to improve bioavailability of essential minerals like iron and zinc in staple grain consumption.

Low phytic acid maize reduces anti-nutritional phytic acid content to improve bioavailability of essential minerals like iron and zinc in staple grain consumption. Used for Micronutrient deficiency (iron and zinc) in populations with maize-dependent diets, Malnutrition in women and children in low-resource settings.

At a glance

Generic name	Low phytic acid maize
Sponsor	NICHD Global Network for Women's and Children's Health
Modality	Small molecule
Therapeutic area	Nutrition / Public Health
Phase	Phase 3

Mechanism of action

Phytic acid (inositol hexaphosphate) is a naturally occurring compound in grains that binds minerals and reduces their absorption in the human gastrointestinal tract. By genetically reducing phytic acid levels in maize, the bioavailability of micronutrients—particularly iron and zinc—is enhanced, improving nutritional status in populations reliant on maize as a primary carbohydrate source. This addresses micronutrient deficiency, particularly in low-resource settings where dietary diversity is limited.

Approved indications

Micronutrient deficiency (iron and zinc) in populations with maize-dependent diets
Malnutrition in women and children in low-resource settings

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low phytic acid maize CI brief — competitive landscape report
Low phytic acid maize updates RSS · CI watch RSS
NICHD Global Network for Women's and Children's Health portfolio CI

Frequently asked questions about Low phytic acid maize

What is Low phytic acid maize?

Low phytic acid maize is a Small molecule drug developed by NICHD Global Network for Women's and Children's Health, indicated for Micronutrient deficiency (iron and zinc) in populations with maize-dependent diets, Malnutrition in women and children in low-resource settings.

How does Low phytic acid maize work?

Low phytic acid maize reduces anti-nutritional phytic acid content to improve bioavailability of essential minerals like iron and zinc in staple grain consumption.

What is Low phytic acid maize used for?

Low phytic acid maize is indicated for Micronutrient deficiency (iron and zinc) in populations with maize-dependent diets, Malnutrition in women and children in low-resource settings.

Who makes Low phytic acid maize?

Low phytic acid maize is developed by NICHD Global Network for Women's and Children's Health (see full NICHD Global Network for Women's and Children's Health pipeline at /company/nichd-global-network-for-women-s-and-children-s-health).

What development phase is Low phytic acid maize in?

Low phytic acid maize is in Phase 3.

Manufacturer: NICHD Global Network for Women's and Children's Health — full pipeline
Therapeutic area: All drugs in Nutrition / Public Health
Indication: Drugs for Micronutrient deficiency (iron and zinc) in populations with maize-dependent diets
Indication: Drugs for Malnutrition in women and children in low-resource settings
Compare: Low phytic acid maize vs similar drugs
Pricing: Low phytic acid maize cost, discount & access